Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 - 75~* elevated serum Insulin-like growth factor-1 (IGF-1) level above age- and sex-based normal values and failure of growth hormone(GH) suppression to \< 1.0 ng/ml after a 75 gm oral glucose tolerance test (OGTT) American Association of Clinical Endocrinolgists (AACE) Acromegaly Clinical Guidelines 2004~* visible pituitary adenoma (microadenoma or macroadenoma) on high quality pituitary MRI without and with gadolinium~* prior treatments for acromegaly with surgery, somatostatin analogs or pegvisomant are acceptable if these therapies have been discontinued for at least 3 months prior to study entry~Exclusion Criteria:~* Age \< 18 or \> 75 years~* acromegalic patients currently on a lanreotide or octreotide preparation or on pegvisomant~* patients who have received prior radiotherapy or radiosurgery~* patients with adenoma-related visual acuity or visual field deficit from optic nerve and/or chiasm compression or severe optic nerve/chiasm compression in the setting of normal visual fields and acuity~* patients with pituitary apoplexy defined as recent tumor hemorrhage and/or infarction on MRI with associated symptoms of new onset visual loss, diplopia and/or adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Somatuline Depot Subcutaneous (SC) (Type: EXPERIMENTAL): Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.

Based on this trial design, predict the completion outcome and termination type (if applicable).